Fernandez Luis E, Gabri Mariano R, Guthmann Marcelo D, Gomez Roberto E, Gold Silvia, Fainboim Leonardo, Gomez Daniel E, Alonso Daniel F
Vaccine Department, Center of Molecular Immunology, Havana, Cuba.
Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27.
Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.
主动特异性免疫疗法是癌症研究中一个很有前景的领域。N-糖基化（NGc）神经节苷脂，尤其是NGcGM3，作为癌症治疗的一个特殊靶点受到了关注。已经开展了许多临床试验，使用含抗NGc神经节苷脂的抗独特型单克隆抗体雷卡妥单抗（原名1E10）以及共轭NGcGM3/VSSP疫苗来治疗黑色素瘤、乳腺癌和肺癌。本文探讨了NGc神经节苷脂在肿瘤生物学中的作用以及这些疫苗产品现有的临床前和临床数据。还简要讨论了癌症抗原在疫苗开发中优先排序的相关性。
